


## Tizanidine-d<sub>4</sub>

<b>Cat. No.:</b>	HY-B0194S		
<b>CAS No.:</b>	1188331-19-2		
<b>Molecular Formula:</b>	C <sub>9</sub> H <sub>4</sub> D <sub>4</sub> ClN <sub>3</sub> S		
<b>Molecular Weight:</b>	257.74		
<b>Target:</b>	Adrenergic Receptor		
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### BIOLOGICAL ACTIVITY

<b>Description</b>	Tizanidine-d <sub>4</sub> is the deuterium labeled Tizanidine. Tizanidine is an α <sub>2</sub> -adrenergic receptor agonist and inhibits neurotransmitter release from CNS noradrenergic neurons[1][2].
<b>In Vitro</b>	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-216.
- [2]. Kamen L, et al. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. *Curr Med Res Opin.* 2008 Feb;24(2):425-39.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA